文献速递间质性肺疾病呼吸道感染

间质性肺疾病患者COVID-19住院结局:国际多中心研究

Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study.
PubMed 文献 · Am J Respir Crit Care Med · 2020-01-01

该国际多中心研究比较了间质性肺疾病(ILD)与非ILD的COVID-19住院患者生存情况。FVC<80%和肥胖的ILD患者死亡风险进一步升高。

要点

  • ILD患者COVID-19住院死亡率高达49%(79/161)。
  • 匹配后ILD患者生存显著差于无ILD对照(HR 1.60,P=0.003)。
  • FVC<80%及肥胖的ILD患者死亡风险更高,需严格预防感染。

核心结论

  • ILD患者因COVID-19住院死亡风险显著高于年龄、性别和合并症匹配的无ILD患者。
  • 肺功能差(FVC<80%)和肥胖的ILD患者死亡风险进一步升高。
  • 对ILD患者应采取严格措施避免感染COVID-19。

研究设计与样本

  • 国际多中心审计,纳入2020年3月1日至5月1日住院的既往诊断ILD且患COVID-19的患者。
  • 对照来自ISARIC4C队列同期COVID-19住院的无ILD患者,按年龄、性别和合并症进行倾向评分匹配。
  • 共纳入欧洲349例ILD患者,其中161例符合条件进入匹配分析。
  • 主要结局为生存,次要分析区分特发性肺纤维化与非特发性肺纤维化ILD并利用肺功能评估死亡风险。

主要发现

  • ILD合并COVID-19患者总体死亡率为49%(79/161)。

临床怎么用

  • 对ILD患者应强化COVID-19预防措施以降低感染和死亡风险。
  • 评估ILD患者COVID-19风险时可关注肺功能(FVC)和肥胖状态。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: The impact of coronavirus disease (COVID-19) on patients with interstitial lung disease (ILD) has not been established.Objectives: To assess outcomes in patients with ILD hospitalized for COVID-19 versus those without ILD in a contemporaneous age-, sex-, and comorbidity-matched population.Methods: An international multicenter audit of patients with a prior diagnosis of ILD admitted to the hospital with COVID-19 between March 1 and May 1, 2020, was undertaken and compared with patients without ILD, obtained from the ISARIC4C (International Severe Acute Respiratory and Emerging Infection Consortium Coronavirus Clinical Characterisation Consortium) cohort, admitted with COVID-19 over the same period. The primary outcome was survival. Secondary analysis distinguished idiopathic pulmonary fibrosis from non-idiopathic pulmonary fibrosis ILD and used lung function to determine the greatest risks of death.Measurements and Main Results: Data from 349 patients with ILD across Europe were included, of whom 161 were admitted to the hospital with laboratory or clinical evidence of COVID-19 and eligible for propensity score matching. Overall mortality was 49% (79/161) in patients with ILD with COVID-19. After matching, patients with ILD with COVID-19 had significantly poorer survival (hazard ratio [HR], 1.60; confidence interval, 1.17-2.18; P = 0.003) than age-, sex-, and comorbidity-matched controls without ILD. Patients with an FVC of <80% had an increased risk of death versus patients with FVC ≥80% (HR, 1.72; 1.05-2.83). Furthermore, obese patients with ILD had an elevated risk of death (HR, 2.27; 1.39-3.71).Conclusions: Patients with ILD are at increased risk of death from COVID-19, particularly those with poor lung function and obesity. Stringent precautions should be taken to avoid COVID-19 in patients with ILD.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Drake TM, Docherty AB, Harrison EM, et al. Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. Am J Respir Crit Care Med. 2020. PMID: 33007173. doi:10.1164/rccm.202007-2794OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。